1 Min Read
Dec 14 (Reuters) - Intercept Pharmaceuticals Inc
* European Commission grants Intercept'S Ocaliva(obeticholic acid) marketing authorization for the treatment of primary biliary cholangitis Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.